{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:53:03Z","timestamp":1773287583644,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development (AMED)","award":["JP23ama121008"],"award-info":[{"award-number":["JP23ama121008"]}]},{"name":"Japan Agency for Medical Research and Development (AMED)","award":["JP23am0401013"],"award-info":[{"award-number":["JP23am0401013"]}]},{"name":"Japan Agency for Medical Research and Development (AMED)","award":["JP23ck0106730"],"award-info":[{"award-number":["JP23ck0106730"]}]},{"name":"Japan Agency for Medical Research and Development (AMED)","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Agency for Medical Research and Development (AMED)","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Agency for Medical Research and Development (AMED)","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["JP23ama121008"],"award-info":[{"award-number":["JP23ama121008"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["JP23am0401013"],"award-info":[{"award-number":["JP23am0401013"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["JP23ck0106730"],"award-info":[{"award-number":["JP23ck0106730"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Head and neck squamous cell carcinoma (HNSCC) is the most common type of head and neck cancer, and has been revealed as the second-highest expression of CD44 in cancers. CD44 has been investigated as a cancer stem cell marker of HNSCC and plays a critical role in tumor malignant progression. Especially, splicing variant isoforms of CD44 (CD44v) are overexpressed in cancers and considered a promising target for cancer diagnosis and therapy. We developed monoclonal antibodies (mAbs) against CD44 by immunizing mice with CD44v3\u201310-overexpressed PANC-1 cells. Among the established clones, C44Mab-18 (IgM, kappa) reacted with CHO\/CD44v3\u201310, but not with CHO\/CD44s and parental CHO-K1 using flow cytometry. The epitope mapping using peptides that cover variant exon-encoded regions revealed that C44Mab-18 recognized the border sequence between variant 10 and the constant exon 16-encoded sequence. These results suggest that C44Mab-18 recognizes variant 10-containing CD44v, but not CD44s. Furthermore, C44Mab-18 could recognize the human oral squamous cell carcinoma (OSCC) cell line, HSC-3, in flow cytometry. The apparent dissociation constant (KD) of C44Mab-18 for CHO\/CD44v3\u201310 and HSC-3 was 1.6 \u00d7 10\u22127 M and 1.7 \u00d7 10\u22127 M, respectively. Furthermore, C44Mab-18 detected CD44v3\u201310 but not CHO\/CD44s in Western blotting, and endogenous CD44v10 in immunohistochemistry using OSCC tissues. These results indicate that C44Mab-18 is useful for detecting CD44v10 in flow cytometry and immunohistochemistry.<\/jats:p>","DOI":"10.3390\/cimb45070333","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T03:18:38Z","timestamp":1687317518000},"page":"5248-5262","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C44Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas"],"prefix":"10.3390","volume":"45","author":[{"given":"Kenichiro","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Xing, D.T., Khor, R., Gan, H., Wada, M., Ermongkonchai, T., and Ng, S.P. (2021). Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists. Cancers, 13.","DOI":"10.3390\/cancers13225716"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Muzaffar, J., Bari, S., Kirtane, K., and Chung, C.H. (2021). Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13020338"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2019.10.010","article-title":"CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma","volume":"467","author":"Ludwig","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: Therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2006.08.261","article-title":"Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways","volume":"26","author":"Slevin","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: Molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_11","first-page":"235","article-title":"CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells","volume":"6","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1073\/pnas.0610117104","article-title":"Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma","volume":"104","author":"Prince","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial-mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/archoto.2010.219","article-title":"Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma","volume":"136","author":"Davis","year":"2010","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34876","DOI":"10.18632\/oncotarget.26172","article-title":"High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy","volume":"9","author":"Kagami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hagiwara, M., Kikuchi, E., Tanaka, N., Kosaka, T., Mikami, S., Saya, H., and Oya, M. (2018). Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-3988-3"},{"key":"ref_20","first-page":"64","article-title":"Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C(44)Mab-5","volume":"14","author":"Yamada","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Goto, N., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2022). Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105535"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/mab.2021.0028","article-title":"Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using Alanine-Scanning Mutagenesis and Surface Plasmon Resonance","volume":"40","author":"Takei","year":"2021","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/mab.2021.0012","article-title":"Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using the REMAP Method","volume":"40","author":"Asano","year":"2021","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/mab.2021.0023","article-title":"Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method","volume":"40","author":"Asano","year":"2021","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_25","first-page":"1949","article-title":"A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma","volume":"44","author":"Takei","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Kitamura, K., Goto, N., Ishikawa, K., Ouchida, T., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). A Novel Anti-CD44 Variant 3 Monoclonal Antibody C(44)Mab-6 Was Established for Multiple Applications. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202304.0452.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/cimb45030121","article-title":"Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C44Mab-108 for Immunohistochemistry","volume":"45","author":"Suzuki","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kudo, Y., Suzuki, H., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas. Antibodies, 12.","DOI":"10.20944\/preprints202301.0581.v1"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ejima, R., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C(44)Mab-9 for Multiple Applications against Colorectal Carcinomas. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044007"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Ozawa, K., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 7\/8 Monoclonal Antibody, C44Mab-34, for Multiple Applications against Oral Carcinomas. Biomedicines, 11.","DOI":"10.20944\/preprints202302.0437.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/cimb45040238","article-title":"A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 was Developed for Immunohistochemical Analyses Against Colorectal Cancers","volume":"45","author":"Tawara","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbrc.2006.08.171","article-title":"Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain","volume":"349","author":"Kato","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002620050329","article-title":"Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas","volume":"43","author":"Heider","year":"1996","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/0959-8049(95)00420-3","article-title":"Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys","volume":"31a","author":"Heider","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_35","first-page":"5499","article-title":"Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas","volume":"55","author":"Gansauge","year":"1995","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/(SICI)1096-9896(199812)186:4<383::AID-PATH202>3.0.CO;2-A","article-title":"Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse","volume":"186","author":"Heider","year":"1998","journal-title":"J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jomfp.JOMFP_246_18","article-title":"Structure, function and role of CD44 in neoplasia","volume":"23","author":"Mishra","year":"2019","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/bjc.2013.314","article-title":"CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence","volume":"109","author":"Hirata","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-7-29","article-title":"CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells","volume":"7","author":"Erb","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15444","DOI":"10.1073\/pnas.1506943112","article-title":"Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal","volume":"112","author":"Holm","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.10369","article-title":"Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts","volume":"99","author":"Verel","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijmm.2023.5221","article-title":"Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models","volume":"51","author":"Li","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"ref_45","first-page":"100826","article-title":"A cancer-specific anti-podocalyxin monoclonal antibody (60-mG(2a)-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma","volume":"24","author":"Kaneko","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/srep05924","article-title":"A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin","volume":"4","author":"Kato","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Kaneko, M.K., and Kato, Y. (2022). Roles of Podoplanin in Malignant Progression of Tumor. Cells, 11.","DOI":"10.20944\/preprints202201.0280.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/gtc.12972","article-title":"Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model","volume":"27","author":"Ishikawa","year":"2022","journal-title":"Genes Cells"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.omto.2022.07.006","article-title":"Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47\u0394 combination therapy against glioblastoma","volume":"26","author":"Chalise","year":"2022","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains","volume":"4","author":"Shiina","year":"2016","journal-title":"Cancer Immunol. Res."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/7\/333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:57:43Z","timestamp":1760126263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/7\/333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cimb45070333"],"URL":"https:\/\/doi.org\/10.3390\/cimb45070333","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}